Heteroaryl modulators of RAS GTPase
US12180220B2 · kind B2 · utility
0Cited by
3References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 24, 2021 |
| Grant date | Dec 31, 2024 |
| Priority date | — |
| Expiry date | Sep 24, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y306/05002
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject compounds can inhibit the growth of cancer cells whose progression is driven by kRAS or a mutated kRAS. Methods of treating a subject for a RAS driven disease including administering a therapeutically effective amount of the subject compound are provided. Also provided are pharmaceutical compositions and kits which include the subject compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.